183 related articles for article (PubMed ID: 31920193)
1. New Oral Anti-Cancer Drugs and Medication Safety.
Schlichtig K; Dürr P; Dörje F; Fromm MF
Dtsch Arztebl Int; 2019 Nov; 116(46):775-782. PubMed ID: 31920193
[TBL] [Abstract][Full Text] [Related]
2. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
[TBL] [Abstract][Full Text] [Related]
3. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Lam MS; Cheung N
J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
[TBL] [Abstract][Full Text] [Related]
4. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
[TBL] [Abstract][Full Text] [Related]
5. [Acceptance of an oncologic addendum for the application of the German Standardized Medication Plan in oral anticancer drug therapy].
Barnert AK; Hofmann P; Liekweg A; Kunze A; Scheid C; Hermes-Moll K; Osburg S; Jaehde U
Z Evid Fortbild Qual Gesundhwes; 2022 Dec; 175():29-42. PubMed ID: 36372643
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.
Arthurs G; Simpson J; Brown A; Kyaw O; Shyrier S; Concert CM
JBI Database System Rev Implement Rep; 2015 Jun; 13(5):244-92. PubMed ID: 26455611
[TBL] [Abstract][Full Text] [Related]
7. Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists.
Timmers L; Boons CC; Verbrugghe M; van den Bemt BJ; Van Hecke A; Hugtenburg JG
BMC Cancer; 2017 Feb; 17(1):122. PubMed ID: 28187759
[TBL] [Abstract][Full Text] [Related]
8. Adherence to oral cancer therapies: nursing interventions.
Winkeljohn D
Clin J Oncol Nurs; 2010 Aug; 14(4):461-6. PubMed ID: 20682501
[TBL] [Abstract][Full Text] [Related]
9. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.
Foulon V; Schöffski P; Wolter P
Acta Clin Belg; 2011; 66(2):85-96. PubMed ID: 21630604
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of antineoplastic agents: the challenges for healthcare professionals.
Tadic D; Spasojevic IB; Tomasevic ZI; Dejanovic SD
J BUON; 2015; 20(3):690-8. PubMed ID: 26214619
[TBL] [Abstract][Full Text] [Related]
11. Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice.
Holle LM; Puri S; Clement JM
J Oncol Pharm Pract; 2016 Jun; 22(3):511-6. PubMed ID: 25900102
[TBL] [Abstract][Full Text] [Related]
12. Improving adherence to oral cancer therapy in clinical practice.
McCue DA; Lohr LK; Pick AM
Pharmacotherapy; 2014 May; 34(5):481-94. PubMed ID: 24877187
[TBL] [Abstract][Full Text] [Related]
13. Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.
Liewer S; Huddleston AN
Expert Rev Anticancer Ther; 2015 Apr; 15(4):453-64. PubMed ID: 25683755
[TBL] [Abstract][Full Text] [Related]
14. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.
Ribed A; Escudero-Vilaplana V; Romero-Jimenez RM; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2016; 15(4):427-35. PubMed ID: 26854363
[TBL] [Abstract][Full Text] [Related]
15. Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations.
Reff MJ; Shillingburg A; Shah B; Elder C; Prescott H; Kennerly-Shah J
J Oncol Pharm Pract; 2020 Jan; 26(1):156-174. PubMed ID: 31354102
[TBL] [Abstract][Full Text] [Related]
16. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review.
Verbrugghe M; Verhaeghe S; Lauwaert K; Beeckman D; Van Hecke A
Cancer Treat Rev; 2013 Oct; 39(6):610-21. PubMed ID: 23428230
[TBL] [Abstract][Full Text] [Related]
17. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy.
Muluneh B; Deal A; Alexander MD; Keisler MD; Markey JM; Neal JM; Bernard S; Valgus J; Dressler LG
J Oncol Pharm Pract; 2018 Mar; 24(2):98-109. PubMed ID: 27895220
[TBL] [Abstract][Full Text] [Related]
18. Medication adherence and the use of new pharmaceutical formulations: the case of levothyroxine.
Scavone C; Sportiello L; Cimmaruta D; Sullo MG; Vitelli B; Rafaniello C; Fossati T; Rossi F
Minerva Endocrinol; 2016 Jun; 41(2):279-89. PubMed ID: 27015567
[TBL] [Abstract][Full Text] [Related]
19. [ADHERENCE TO ORAL ANTI-CANCER DRUGS IN HEMATO-ONCOLOGY].
Ashkenazi S; Dreyer J; Raanani P; Leader A
Harefuah; 2017 Apr; 156(4):254-258. PubMed ID: 28551924
[TBL] [Abstract][Full Text] [Related]
20. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.
Hosoya K; Mochinaga S; Emoto A; Yokoo H; Tokushima H; Egoshi M; Sueoka-Aragane N; Kimura S
Int J Clin Oncol; 2015 Dec; 20(6):1203-10. PubMed ID: 26002407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
